The mechanism of topotecan resistance in ovarian cancer cell line

• Published in: Zhōnghuá zhŏngliú zázhì Vol. 26; no. 3; p. 139
• Main Authors: Jia, Ping, Wu, Shao-Bo, Li, Fang, Xu, Qian, Wu, Ming-Fu, Liao, Guo-Ning, Lu, Yun-Ping, Ma, Ding
• Format: Journal Article
• Language: Chinese
• Published: China 01.03.2004
• Subjects: Antineoplastic Agents - pharmacology; ATP Binding Cassette Transporter, Sub-Family G, Member 2; ATP-Binding Cassette Transporters - genetics; ATP-Binding Cassette, Sub-Family B, Member 1 - genetics; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins - genetics; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - pathology; RNA, Messenger - analysis; Topotecan - pharmacology
• ISSN: 0253-3766

To study the mechanism of topotecan (TPT) resistance in ovarian cancer cell line. A TPT-resistant ovarian cancer cell line A2780/TPT established in this laboratory was used in this study. Intracellular rhodamine fluorescence intensity of the TPT-resistant cells and parental cells were measured by flow cytometry. The gene expression of membrane protein transporter such as transporter P-glycoprotein (P-gp), multidrug resistance associated protein (MRP), breast cancer resistance protein (BCRP) was evaluated by RT-PCR. The antisense-phosphorothioate oligonucleotide (ASODN) including a translation initiation site of BCRP mRNA was transferred into resistant cells by liposome. Intracellular rhodamine fluorescence intensity of the resistant cells was 31.19% of that in the parental cells (P < 0.01). No expression of P-gp was demonstrated, and that of MRP was very weak in the TPT-resistant cells (relative expression value = 0.057). BCRP was overexpressed in the TPT-resistant cells (relative expression = 0.66), but not